Cart
sales@molnova.com
Cudetaxestat
CAS No. 1782070-21-6
Cudetaxestat( —— )
Catalog No. M35705 CAS No. 1782070-21-6
Cudetaxestat (BLD-0409) is a potent, orally active autotaxin inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 169 | In Stock |
|
| 5MG | 164 | In Stock |
|
| 10MG | 247 | In Stock |
|
| 25MG | 444 | In Stock |
|
| 50MG | 647 | In Stock |
|
| 100MG | 910 | In Stock |
|
| 200MG | 1200 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCudetaxestat
-
NoteResearch use only, not for human use.
-
Brief DescriptionCudetaxestat (BLD-0409) is a potent, orally active autotaxin inhibitor.
-
DescriptionCudetaxestat (BLD-0409) is a potent and orally active autotaxin (ATX) inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1782070-21-6
-
Formula Weight482.33
-
Molecular FormulaC21H15Cl2F2N3O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (518.32 mM; Ultrasonic )
-
SMILESCCCn1cc(cn1)-n1c(Cl)c(Sc2cccc(C(O)=O)c2F)c2ccc(Cl)c(F)c12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tan Z, et al. An updated patent review of autotaxin inhibitors (2017-present). Expert Opin Ther Pat. 2021;31(5):421-434. ?
molnova catalog
related products
-
Verofylline
Verofylline (Verofyllinum) is an orally available, long-acting, multiacting, methylxanthine-substituted bronchodilator with inhibitory effects on PDE4 for the treatment of asthma disease research obesity.
-
Ensifentrine
Ensifentrine is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.
-
PDE IV-IN-1
PDE IV-IN-1 is a potent phosphodiesterase 4 (PDE4) inhibitor with anti-inflammatory activity for the treatment of asthma, chronic obstructive pulmonary disease and other inflammatory diseases, and is a potential compound for the study of depression.
